Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Opiate dependence remains a fundamental challenge confronting health delivery systems and is often characterized as a social and moral issue. The impact of this disorder on healthcare policy is changing with the increased incidence of HIV, hepatitis C, and tuberculosis infections in opiate-dependent patients. These medical illnesses have substantial effect on escalating healthcare costs, and, therefore, also affect healthcare policy priorities, which are responsive to these costs. Pharmacological treatments for opiate dependence have had limited success; often the consequence of limited access to care. Hence, there is a need to develop new pharmacotherapies for opiate dependence that extend the range of clinical options, including new first-line treatment approaches. This paper will focus on the safety and health policy considerations related to the use of buprenorphine and buprenorphine/naloxone based on data derived from clinical trials and post-marketing surveillance that provide evidence for the use of the medications as first-line treatments in an office-based environment. The evaluation of this evidence formed the basis by the National Institute on Drug Abuse to support and pursue the evaluation and registration of buprenorphine/naloxone and buprenorphine in a public/private sector cooperative effort to become an office-based, first-line treatment for opiate dependence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although methadone is superior to buprenorphine in improving addiction outcomes in opioid-dependent patients, buprenorphine has a better safety profile.21–23, 25”
From A Preliminary Study Comparing Methadone and Buprenorphine in Patients with Chronic Pain and Coexistent Opioid Addiction (2013) · cites this paper as [23]
In the citing paper
“Buprenorphine, a partial μ-opioid receptor agonist and κ-opioid receptor antagonist with a half-life of 2.33 ± 0.24 hours might be an alternative to methadone because it is effective in treating opioid addiction or pain.21–26”
From A Preliminary Study Comparing Methadone and Buprenorphine in Patients with Chronic Pain and Coexistent Opioid Addiction (2013) · cites this paper as [23]
In the citing paper
“Although methadone is superior to buprenorphine in improving addiction outcomes in opioid-dependent patients, buprenorphine has a better safety profile.21–23, 25”
From A Preliminary Study Comparing Methadone and Buprenorphine in Patients with Chronic Pain and Coexistent Opioid Addiction (2013) · cites this paper as [23]
Citations
Cites
The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome
Ball, J. C., & Ross, A. O. (1991) · Cited by 903
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773 · cited 1×
“While buprenorphine alone has been documented to demonstrate a ceiling to respiratory depressant effects in clinical pharmacological testing (Walsh et al., 1994), the interaction of buprenorphine with other CNS depressants such as benzodiazepines and alcohol may be potentially serious or lethal, and practitioners are…”
BackgroundA Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
The Effectiveness of Methadone Maintenance Treatment
Ball, J. C., & Ross, A. (1991) · Springer eBooks · doi:10.1007/978-1-4613-9089-3 · Cited by 590
Effective Medical Treatment of Opiate Addiction
Addiction, N. C. D. P. O. E. M. T. O. O. (1998) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.280.22.1936 · Cited by 577
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480200058024 · Cited by 572
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
Comparison of buprenorphine and methadone in the treatment of opioid dependence
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.1025 · Cited by 305
Deaths involving buprenorphine: a compendium of French cases
Kintz, P. (2001) · Forensic Science International · doi:10.1016/s0379-0738(01)00454-6 · Cited by 233
Cited by
Babor, T. F., McRee, B. G., Kassebaum, P. A., Grimaldi, P. L., Ahmed, K., & Bray, J. (2007) · Substance Abuse · doi:10.1300/j465v28n03_03 · Cited by 1,100
“The decision to allow office based treatment of buprenorphine was based on a large body of clinicalexperiencefromothercountriesandthe United States (76-78).”
BackgroundBuprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review
A. Yokell, M., D. Zaller, N., C. Green, T., & D. Rich, J. (2011) · Current Drug Abuse Reviewse · doi:10.2174/1874473711104010028 · Cited by 398
Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine
Kress, H. G. (2009) · European Journal of Pain · doi:10.1016/j.ejpain.2008.04.011 · Cited by 238
Pharmacokinetics of the combination tablet of buprenorphine and naloxone
CHIANG, C. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00058-9 · Cited by 186
Twelve Reasons for Considering Buprenorphine as a Frontline Analgesic in the Management of Pain
Davis, M. P. (2012) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2012.05.002 · Cited by 179
Metadata
- Authors
- BRIDGE, T.
- Affiliations
- National Institute on Drug Abuse (US)
- Corresponding author
- BRIDGE, T
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2003-05
- Volume
- 70
- Issue
- 2
- Pages
- S79-S85
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2104235909
- Cited by
- 63
- References
- 60
- Citations by year
- 2025: 2 · 2023: 1 · 2022: 2 · 2021: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 4 · 2014: 2 · 2013: 5 · 2012: 7
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Drug and Alcohol Dependence (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institute on Drug Abuse (3YO1-DA-30011-04)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- buprenorphine/naloxone, buprenorphine, opioid use disorder, office-based treatment, first-line therapy, healthcare policy, drug safety, post-marketing surveillance, HIV, hepatitis C, tuberculosis, health care costs, health care access
- MeSH terms
- Buprenorphine, Naloxone Drug Combination, Buprenorphine, Clinical Trials as Topic, Drug Combinations, Health Policy, Humans, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Office Visits, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. https://app.cochat.ai/papers/10.1016/s0376-8716(03)00061-9
- The paper
- BRIDGE, T. (2003). Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug and Alcohol Dependence. https://doi.org/10.1016/s0376-8716(03)00061-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.